The company’s Phase III trial of nemvaleukin alfa alongside Keytruda saw just a 0.3 month gain in overall survival over other ...

Mural Oncology's stock plummeted 57% after halting the Phase 3 ARTISTRY-7 trial for nemvaleukin alfa. Click here to read an ...

Mural Oncology ends nemvaleukin development for ovarian cancer after ARTISTRY-7 trial misses survival goals. Phase 2 trials ...

Mural Oncology (NASDAQ:MURA – Get Free Report) was downgraded by stock analysts at Raymond James from a “strong-buy” rating ...

Mural Oncology said that it won't continue developing its ovarian cancer drug candidate Nemvaleukin to be used in conjunction with Merck's Keytruda after results showed no statistical improvement in ...

H.C. Wainwright analyst Andres Maldonado lowered the firm’s price target on Mural Oncology (MURA) to $6 from $18 and keeps a Buy rating on the ...

According to MarketBeat.com, Mural Oncology has a consensus rating of “Moderate Buy” and a consensus price target of $13.00. Read Our Latest Stock Report on MURA Mural Oncology Trading Down 12.6 % ...

Mural Oncology (NASDAQ:MURA) stock plummets 47% as the company, a spinoff of Alkermes (ALKS) halts a Phase 3 trial for its ...

A Waltham company pulled the plug on a Phase 3 cancer trial, while a different Waltham company continued its leadership ...

Indio has a new mural that's meaning goes beyond creative art. Artist Patrick Barwinski created the "Desi Memorial Mural," in ...